Published in Cell on June 30, 2006
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev (2010) 6.05
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell (2008) 4.90
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol (2011) 4.63
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
A census of amplified and overexpressed human cancer genes. Nat Rev Cancer (2010) 4.47
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A (2010) 4.17
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A (2007) 3.84
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
IAPs: what's in a name? Mol Cell (2008) 3.66
The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol (2008) 3.63
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
In vivo regulation of Yorkie phosphorylation and localization. Development (2008) 3.51
Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev (2012) 3.48
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 3.47
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (2012) 3.41
The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev (2010) 3.37
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 3.33
CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature (2014) 3.28
YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol (2009) 3.26
The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A (2010) 3.18
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev (2011) 3.15
Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell (2014) 3.15
KRAS and YAP1 converge to regulate EMT and tumor survival. Cell (2014) 3.06
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 3.03
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A (2008) 2.98
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev (2009) 2.58
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A (2012) 2.51
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell (2014) 2.50
A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J (2008) 2.46
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev (2011) 2.29
The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol (2012) 2.21
Hippo signaling regulates Drosophila intestine stem cell proliferation through multiple pathways. Proc Natl Acad Sci U S A (2010) 2.16
Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Dev Cell (2010) 2.13
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol (2008) 2.11
Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A (2009) 2.07
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
In vivo analysis of Yorkie phosphorylation sites. Oncogene (2009) 2.00
Structural insights into the YAP and TEAD complex. Genes Dev (2010) 2.00
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008) 1.97
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene (2009) 1.97
TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem (2009) 1.96
The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration. Development (2010) 1.89
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86
Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep (2012) 1.81
Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol (2009) 1.81
Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One (2013) 1.81
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev (2010) 1.80
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res (2010) 1.77
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Phosphorylation of the tumor suppressor fat is regulated by its ligand Dachsous and the kinase discs overgrown. Curr Biol (2009) 1.74
The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep (2014) 1.73
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem (2009) 1.68
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Yorkie: the final destination of Hippo signaling. Trends Cell Biol (2010) 1.65
Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol (2009) 1.64
14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell (2015) 1.63
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev (2010) 1.61
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol (2008) 1.59
Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse. Mol Cell Biol (2009) 1.58
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
The hallmarks of cancer. Cell (2000) 113.05
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Hepatocellular carcinoma. Lancet (2003) 22.54
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell (2005) 10.61
Intrinsic tumour suppression. Nature (2004) 8.73
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol (2002) 7.23
The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol (2005) 6.74
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell (2003) 5.66
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol (1993) 5.15
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J (1999) 4.66
From cell structure to transcription: Hippo forges a new path. Cell (2006) 4.65
From signatures to models: understanding cancer using microarrays. Nat Genet (2005) 4.29
Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet (1999) 4.23
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene (1998) 3.98
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene (2005) 3.64
Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev (2005) 3.59
Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene (1994) 3.19
Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J Cell Biol (1996) 3.13
Induction of apoptosis by Drosophila reaper, hid and grim through inhibition of IAP function. EMBO J (2000) 3.02
Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene (2005) 2.99
Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 2.93
The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 2.71
Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res (2005) 2.67
Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am J Pathol (1998) 2.62
Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol (2005) 2.57
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
Genetic mechanisms of hepatocarcinogenesis. Oncogene (2002) 2.21
Oncogene-induced liver neoplasia in transgenic mice. Oncogene (1989) 2.20
A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet (2003) 2.18
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol (2005) 2.18
Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol (1993) 2.09
Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res (1993) 2.09
Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene (2004) 1.94
A survey of homozygous deletions in human cancer genomes. Proc Natl Acad Sci U S A (2005) 1.94
Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci U S A (2005) 1.91
Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res (2001) 1.78
Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res (2001) 1.74
NDR family of AGC kinases--essential regulators of the cell cycle and morphogenesis. FEBS Lett (2003) 1.65
Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest (2005) 1.55
Liver cancer: the role of stem cells. Cell Prolif (2005) 1.52
Geographic variation of p53 mutational profile in nonmalignant human liver. Science (1994) 1.51
Liver repopulation after cell transplantation in mice treated with retrorsine and carbon tetrachloride. Transplantation (2002) 1.48
Mice without telomerase: what can they teach us about human cancer? Nat Med (2000) 1.33
Purification of fetal mouse hepatoblasts by magnetic beads coated with monoclonal anti-e-cadherin antibodies and their in vitro culture. Exp Cell Res (2002) 1.28
Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology (1994) 1.21
Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc (1993) 1.15
Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. Cold Spring Harb Symp Quant Biol (2005) 1.15
Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. Proc Natl Acad Sci U S A (2001) 1.12
Human Cancer Genome Project moving forward despite some doubts in community. J Natl Cancer Inst (2005) 0.98
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Large-scale copy number polymorphism in the human genome. Science (2004) 34.64
Strong association of de novo copy number mutations with autism. Science (2007) 27.84
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
Genome-wide in situ exon capture for selective resequencing. Nat Genet (2007) 19.97
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell (2007) 18.35
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Dicer is essential for mouse development. Nat Genet (2003) 15.87
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev (2006) 15.20
Processing of primary microRNAs by the Microprocessor complex. Nature (2004) 14.59
Crystal structure of Argonaute and its implications for RISC slicer activity. Science (2004) 12.48
MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol (2005) 12.12
Discovery of functional elements in 12 Drosophila genomes using evolutionary signatures. Nature (2007) 11.66
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Annotating large genomes with exact word matches. Genome Res (2003) 11.07
Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature (2008) 10.71
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev (2002) 10.71
A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature (2006) 9.88
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
De novo gene disruptions in children on the autistic spectrum. Neuron (2012) 9.69
The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science (2007) 9.36
Sorting of small RNAs into Arabidopsis argonaute complexes is directed by the 5' terminal nucleotide. Cell (2008) 9.02
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Small RNAs as guardians of the genome. Cell (2009) 8.88
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Characterization of Dicer-deficient murine embryonic stem cells. Proc Natl Acad Sci U S A (2005) 8.35
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
An endogenous small interfering RNA pathway in Drosophila. Nature (2008) 7.88
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 7.74
Developmentally regulated piRNA clusters implicate MILI in transposon control. Science (2007) 7.68
MIWI2 is essential for spermatogenesis and repression of transposons in the mouse male germline. Dev Cell (2007) 7.66
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev (2002) 7.61
A role for the P-body component GW182 in microRNA function. Nat Cell Biol (2005) 7.54
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet (2008) 7.13
The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol (2003) 6.90
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol (2005) 6.64
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev (2002) 6.43
Specialized piRNA pathways act in germline and somatic tissues of the Drosophila ovary. Cell (2009) 6.39
A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature (2010) 6.37
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice. Mol Cell (2008) 6.35
A role for Piwi and piRNAs in germ cell maintenance and transposon silencing in Zebrafish. Cell (2007) 6.31
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science (2010) 5.84
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron (2011) 5.78
Genome analysis of the platypus reveals unique signatures of evolution. Nature (2008) 5.74
Alta-Cyclic: a self-optimizing base caller for next-generation sequencing. Nat Methods (2008) 5.70
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Cancer proliferation gene discovery through functional genomics. Science (2008) 5.41
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
RNA interference in adult mice. Nature (2002) 5.33
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A (2005) 5.29
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci U S A (2007) 5.16
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A (2002) 5.05